Liste de publications du groupe fonctionnel Sentinelle COVID Québec 

Ressources web

Données sur les variants du SRAS-CoV-2 au Québec

2022

Laumaea AE., Lewin A., Chatterjee D., Marchitto L., Ding S., Gendron-Lepage G., Goyette G., Allard ME., Simard C., Tremblay T., Perreault J., Duerr R., Finzi A#., and Bazin R#. COVID-19 vaccine humoral response in frequent platelet donors with plateletpheresis-associated lymphopenia. Transfusion. 2022. In press. #co-corresponding

 Nayrac M, Dubé M, Sannier G, Nicolas A, Marchitto L, Tastet O, Tauzin A, Brassard N, Beaudoin-Bussières G, Vézina D, Gong SY, Benlarbi M, Gasser R, Laumaea A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Ortega-Delgado GG, Laporte M, Niessl J, Gokool L, Morrisseau C, Arlotto P, Richard J, Tremblay C, Martel-Laferrière V, Finzi A, Kaufmann DE. Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. Cell Reports Published:June 12, 2022DOI:https://doi.org/10.1016/j.celrep.2022.111013

Ding S, Ullah I, Gong SY, Grover JR, Mohammadi M, Chen Y, Vézina D, Beaudoin-Bussières G, Verma VT, Goyette G, Gaudette F, Richard J, Yang D, Smith AB 3rd, Pazgier M, Côté M, Abrams C, Kumar P, Mothes W, Uchil PD, Finzi A, Baron C. VE607 stabilizes SARS-CoV-2 Spike in the « RBD-up » conformation and inhibits viral entry. iScience. 2022 Jul 15;25(7):104528. doi: 10.1016/j.isci.2022.104528. Epub 2022 Jun 3. PMID: 35677392; PMCID: PMC9164512.

Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V, Trottier B, Richard J, Durand M, Kaufmann D, Finzi A, Tremblay C. Covid-19 vaccine immunogenicity in people living with HIV-1. Vaccine. 2022 Jun 9;40(26):3633-3637. doi: 10.1016/j.vaccine.2022.04.090. Epub 2022 May 5. PMID: 35568588; PMCID: PMC9069249.

*Cité par le Comité sur l’immunisation du Québec dans: Avis portant sur la pertinence d’une dose additionnelle de vaccin contre la COVID-19 pour les personnes ayant une immunodépression

Lewin A, De Serres G, Grégoire Y, Perreault J, Drouin M, Fournier MJ, Tremblay T, Beaudoin J, Boivin A, Goyette G, Finzi A, Bazin R, Germain M, Delage G, Renaud C. Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study. Can J Public Health. 2022 Jun;113(3):385-393. doi: 10.17269/s41997-022-00622-y. Epub 2022 Apr 5. PMID: 35380364; PMCID: PMC8982303.

Beaudoin-Bussières, Guillaume, Ariana Arduini, Catherine Bourassa, Halima Medjahed, Gabrielle Gendron-Lepage, Jonathan Richard, Qinghua Pan, Zhen Wang, Chen Liang, and Andrés Finzi. 2022. « SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity » Viruses 14, no. 6: 1237. https://doi.org/10.3390/v14061237

Tauzin A., Gendron-Lepage G., Nayrac M., Anand SP., Bourassa C., Medjahed H., Goyette G., Dubé M., Bazin R., Kaufmann DE. and Finzi A.  Evolution of anti-RBD IgG avidity following SARS-CoV-2 infection.  Viruses. 2022. In press.

Selected as Editor’s Choice Article

Piret J, Boivin G. Viral Interference between Respiratory Viruses. Emerg Infect Dis. 2022;28(2):273-281. https://doi.org/10.3201/eid2802.211727

Fage, C.; Hénaut, M.; Carbonneau, J.; Piret, J.; Boivin, G. Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2
Replication during Sequential Infections in Human Nasal Epithelial Cells. Viruses 2022, 14, 395. https://doi.org/10.3390/v14020395

Lewin A., De Serres G., Grégoire Y., Perreault J., Drouin M., Fournier MJ., Tremblay T., Beaudoin J., Boivin A., Goyette G., Finzi A., Bazin R., Germain M., Delage G. and Renaud C.  Seroprevalence of SARS-CoV-2 Antibodies Among Blood Donors in Québec: An Update from a Serial Cross-Sectional Study.  Canadian Journal of Public Health. 2022. In press.

Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S.Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., Vézina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, É., Guilbault, A., Delisle, B., Levade, I., Goyette, G., Gendron-Lepage, G., Medjahed, H., De Serres, G., Tremblay, C., Martel-Laferrière, V., Kaufmann, D.E., Bazin, R., Prévost, J., Moreira, S., Richard, J., Côté, M., Finzi, A., SARS-CoV-2 Omicron Spike recognition by plasma
from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses, Cell Reports (2022), doi:https://doi.org/10.1016/j.celrep.2022.110429.

Cited by Public Health Ontario in COVID-19 Variant of Concern Omicron (B.1.1.529): Risk Assessment, January 6, 2022

Yang Z., Han Y., Ding S., Shi W., Zhou T., Finzi A., Kwong P., Mothes W., and Lu M.  SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy.  mBio. 2022 Feb 15;13(1):e0322721. doi: 10.1128/mbio.03227-21

 Tanguay M*., Boutin M*., Laumaea A., Mendoza A., Clark MW., Finzi A#., and Johnson NA#. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-CoV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 2022.  In press. *Contributed equally, #co-corresponding

 Beaudoin-Bussières G*., Chen Y*., Ullah I*., Prévost J., Tolbert WD., Symmes K., Ding S., Benlarbi M., Gong SY., Tauzin A., Gasser R., Chatterjee D., Vézina D., Goyette G., Richard J., Zhou F., Stamatatos L., McGuire AT., Charest H., Roger M., Pozharski E., Kumar P., Mothes W., Uchil PD#., Pazgier M#., and Finzi A#.  A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a NAb to protect mice from lethal SARS-CoV-2 infection.  Cell Reports. 2022. In press.  *co-first, #co-corresponding.

 Tauzin A., Gong SY., Beaudoin-Bussières G., Vézina D., Gasser R., Nault L., Marchitto L., Benlarbi M., Chatterjee D., Nayrac M., Laumaea A., Prévost J., Boutin M., Sannier G., Nicolas A., Bourassa C., Gendron-Lepage G., Medjahed H., Goyette G., Bo Y., Perreault J., Gokool L., Morrisseau C., Arlotto P., Bazin R., Dubé M., De Serres G., Brousseau N., Richard J., Rovito R., Côté M., Tremblay C., Merchetti GC., Duerr R., Martel-Laferrière V#., Kaufmann DE#., and Finzi A#. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccinatio with a 16-week interval between doses.  Cell Host and Microbe. 2022. 30:97-109.  #co-corresponding.  https://doi.org/10.1016/j.chom.2021.12.004

*Cité par le Comité sur l’immunisation du Québec dans: Intervalle entre les doses de la primovaccination avec les vaccins à ARN messager contre la COVID-19

*Cited by News Medical in Researchers encourage longer dosing intervals for Pfizer-BioNTech’s COVID-19 vaccine

 Simard C., Richard J., Bazin R., Finzi A. and Trépanier P. Standardization of a flow cytometry SARS-CoV-2 serologic test.  Cytotechnology. 2022. Jan 3:1-5 doi: 10.1007/s10616-021-00511-1

 Bégin P#., Callum J#., Jamula E., Cook R., Jamula E, Liu Y., Finzi A., CONCOR-1 Study Group and Arnold DM#. Reply to: Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19.  Nature Medicine. 2022. In press. #co-corresponding. doi: 10.1038/s41591-021-01639-5

2021

 Song, L., Liu, H., Brinkman, F., Gill, E., Griffiths, E., Hsiao, W., Savić-Kallesøe, S., Moreira, S., Van Domselaar, G., H. Zawati, M., Joly, Y. (2021) Addressing Privacy Concerns in Sharing Viral Sequences and Minimum Contextual Metadata in a Public Repository during the COVID-19 Pandemic. Frontiers in Genetics. [En révision]

 Chatterjee D., Tauzin A., Laumaea A., Gong SY., Bo Y., Guilbault A., Goyette G., Bourassa C., Gendron-Lepage G., Medjahed H., Richard J., Moreira S., Côté M.,  and Finzi A.  Antigenicity of the Mu (B.1.621) and A.2.5 SARS-COV-2 Spikes.  Viruses. 2021. In press.

 Shilei Ding, Damien Adam, Guillaume Beaudoin-Bussières, Alexandra Tauzin, Shang Yu Gong, Romain Gasser, Annemarie Laumaea, Sai Priya Anand, Anik Privé, Catherine Bourassa, Halima Medjahed, Jérémie Prévost, Hugues Charest, Jonathan Richard, Emmanuelle Brochiero and Finzi A.  SARS-CoV-2 Spike expression at the surface of infected primary human airway epithelial cells.  Viruses. 2021. In press.

Carter-Timofte ME, Arulanandam R, Kurmasheva N, Fu K, Laroche G, Taha Z, van der Horst D, Cassin L, van der Sluis RM, Palermo E, Di Carlo D, Jacobs D, Maznyi G, Azad T, Singaravelu R, Ren F, Hansen AL, Idorn M, Holm CK, Jakobsen MR, van Grevenynghe J, Hiscott J, Paludan SR, Bell JC, Seguin J, Sabourin LA, Côté M, Diallo JS, Alain T, Olagnier D. Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. ACS Infect Dis. 2021 Nov 12;7(11):3034-3051. doi: 10.1021/acsinfecdis.1c00278. Epub 2021 Oct 18. PMID: 34658235

 Coté F, Boivin G, Lougnarath V, Ruest A, Bestman-Smith J, Carbonneau J, Hamelin ME, Roy MC. Duration of Isolation and Contagiousness in COVID-19 Patients Receiving Tocilizumab and Dexamethasone: A Case Series. Infection Control and Hospital EpidemiologyIn revision.

 Tardif JC, Cossette M, Guertin MC, Bouabdallaoui N, Dubé MP, Boivin G. Predictive Risk Factors for Hospitalization and Response to Colchicine in Patients with COVID-19. International Journal of Infectious DiseasesIn revision.

 Piret J, Boivin G. The Concept of Viral Interference Between Respiratory Viruses. Emerging Infectious DiseasesIn press.

 Andrew M, Godin J, LeBlanc J, Boivin G, …McNeil SA. Older Age and Frailty Are Associated with Higher Mortality but Lower Intensive Care Unit Admission With COVID-19. Canadian Geriatrics JournalIn press.

 Li W*., Chen Y*., Prévost J*., Ullah I., Lu M., Gong SY., Tauzin A., Gasser R., Vézina D., Anand SP., Goyette G., Chaterjee D., Ding S., Tolbert WD., Grunst MW., Bo Y., Zhang S., Richard J., Zhou F., Huang RK., Esser L., Zeher A., Côté M., Kumar P., Sodroski J., Xia D., Uchil PD., Pazgier M#., Finzi A#. and Mothes W#.  Structural bases and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern.  Cell Reports. 2021. In press.  *co-first, #co-corresponding.

 Benoit P, Labbé AC, Lalancette L, Gagnon S, Bonneau E, Lavallée C, Roger M, Fafard J, Dumaresq J, Beauchemin S, Coutlée F; G-SPIT group. Comparison of SARS-CoV-2 detection with the Cobas® 6800/8800 system on gargle samples using two sample processing methods with combined oropharyngeal/nasopharyngeal swab. J Med Virol. 2021 Dec;93(12):6837-6840. doi: 10.1002/jmv.27245. Epub 2021 Aug 5.

 Longtin Y, Parkes LO, Charest H, Rajarison S, Zaharatos GJ, Fafard J, Roger M, De Serres G. Persistence of infectivity in elderly individuals diagnosed with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection 10 days after onset of symptoms: A cross-sectional study. Infect Control Hosp Epidemiol. 2021 Dec 6:1-4. doi: 10.1017/ice.2021.502. Epub ahead of print.

 Valcourt E., Manguiat K., Robinson A., Lin YC., Abe K., Mubareka S., Shigayeva A., Zhong Z., Girardin R., Dupuis A,. Payne A., McDonogh K., Wang Z., Gasser R., Laumaea A., Benlarbi M., Richard J., Prévost J., Anand SP., Dimitrova K., Phillipson C., McGreer A., Gingras AC., Liang C., Petric M., Sekirov I., Morshed M., Finzi A., Drebot M., Wood H.  Evaluating humoral immunity against SARS-CoV-2: validation of a plaque-reduction neutralization test and a multi-laboratory comparison of conventional and surrogate neutralization assays. Spectrum. 2021. Nov 17:e0088621. doi: 10.1128/Spectrum.00886-21

 Dumaresq J, Coutlée F, Dufresne PJ, Longtin J, Fafard J, Bestman-Smith J, Bergevin M, Vallières E, Desforges M, Labbé AC. Natural spring water gargle and direct RT-PCR for the diagnosis of COVID-19 (COVID-SPRING study). J Clin Virol. 2021 Nov;144:104995. doi: 10.1016/j.jcv.2021.104995. Epub 2021 Oct 2.

 Gobeille Paré S, Bestman-Smith J, Fafard J, Doualla-Bell F, Jacob-Wagner M, Lavallée C, Charest H, Beauchemin S, Coutlée F, Dumaresq J, Busque L, St-Hilaire M, Lépine G, Boucher V, Desforges M, Goupil-Sormany I, Labbé AC; G-SPIT study group. Natural spring water gargle samples as an alternative to nasopharyngeal swabs for SARS-CoV-2 detection using a laboratory-developed test. J Med Virol. 2021 Oct 21:10.1002/jmv.27407. doi: 10.1002/jmv.27407. Epub ahead of print.

 Labbé AC, Benoit P, Gobeille Paré S, Coutlée F, Lévesque S, Bestman-Smith J, Dumaresq J, Lavallée C, Houle C, Martin P, Mak A, Gervais P, Langevin S, Jacob-Wagner M, Gagnon S, St-Hilaire M, Lussier N, Yechouron A, Roy D, Roger M, Fafard J. Comparison of saliva with oral and nasopharyngeal swabs for SARS-CoV-2 detection on various commercial and laboratory-developed assays. J Med Virol. 2021 Sep;93(9):5333-5338. doi: 10.1002/jmv.27026. Epub 2021 May 3.

 Cai T, Yu Z, Wang Z, Liang C, Richard S. Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication. J Biol Chem. 2021 Jul;297(1):100821. doi: 10.1016/j.jbc.2021.100821. Epub 2021 May 23. PMID: 34029587; PMCID:PMC8141346.

 Zhao J, Guo S, Yi D, Li Q, Ma L, Zhang Y, Wang J, Li X, Guo F, Lin R, LiangC, Liu Z, Cen S. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 2021 Jun;190:105078. doi: 10.1016/j.antiviral.2021.105078. Epub 2021 Apr 21. PMID: 33894278; PMCID:PMC8059291.

 Li Q, Yi D, Lei X, Zhao J, Zhang Y, Cui X, Xiao X, Jiao T, Dong X, Zhao X, Zeng H, Liang C, Ren L, Guo F, Li X, Wang J, Cen S. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta Pharm Sin B. 2021 Jun;11(6):1555-1567. doi: 10.1016/j.apsb.2021.02.011. Epub 2021 Feb 15. PMID: 33614402; PMCID: PMC7883726.

 REMAP-CAP Investigators, Estcourt LJ., Turgeon AF., McQuilten ZK., McVerry BJ., Al-Beidh F., Annane D., Arabi YM., Arnold DM., Beaine A., Bégin P., van Bentum-Puijk W., Berry LR., Bhimani Z., Birchall JE., Bonten MJM., Bradbury CA., Brunkhorst FM., Buxton M., Callum JL., Chassé M., Cheng AC., Cove ME., Daly J., Derde L., Detry MA., De Jong M., Evans A., Fergusson DA., Fish M., Fitzgerald M., Foley C., Goossens H., Gordon AC., Gosbell IB., Green C., Haniffa R., Harvala H., Higgins AM., Hills TE., Hoad VC., Horvat C., Huang DT., Hudson CL., Ichihara N., Laing E., Lamikanra AA., Lamontagne F., Lawler PR., Linstrum K., Litton E., Lorenzi E., MacLennan S., Marschall J., McAuley DF., McDyer JF., McGlothlin A., McGuinness S., Miflin G., Montgomery S., Moncey PR., Murthy S., Nichol A., Parke R., Parker JC., Priddee N., Purcell DFJ., Reyes LF., Richardson P., Robitaille N., Rowan KM., Rynne J., Saito H., Santos M., Saunders CT., Serpa Neto A., Seymour CW., Silversides JA., Tinmouth AA., Triulzi DJ., Turner AM., van de Veerdonk F., Walsh TS., Wood EM., Berry S., Lewis RJ., Menon DK., McArthur C., Zarychanski R., Angus DC., Webb SA., Roberst DJ., Shankar-Hari M.   Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.  JAMA. 2021. Oct 4. doi: 10.1001/jama.2021.18178

 Brunet-Ratnasingham E*., Anand SP*., Gantner P*., Dyachenko A., Moquin-Beaudry G., Brassard N., Beaudoin-Bussières G., Pagliuzza A., Gasser R., Benlarbi M., Point F., Prévost J., Laumaea A., Niessl J., Nayrac M., Sannier G., Orban C., Messier-Peet M., Butler-Laporte G., Morrison DR., Zhou S., Nakanishi T., Boutin M., Descôteaux-Dinelle J., Gendron-Lepage G., Goyette G., Bourassa C., Medjahed H., Laurent L., Rébillard RM., Richard J., Dubé M., Fromentin R., Arbour N., Prat A., Larochelle C., Durand M., Richards JB., Chassé M., Tétreault M., Chomont N#., Finzi A#., and Kaufmann DE#. Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.  Science Advances. 2021. Nov 26;7(48):eabj5629. doi: 10.1126/sciadv.abj5629. *co-first, #co-corresponding

 Gong SY*, Chatterjee D*., Richard J., Prévost J., Tauzin A., Gasser R., Bo Y., Vézina D., Goyette G., Gendron-Lepage G., Medjahed H., Roger M., Côté M. and Finzi A.  Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity.  Virology. 2021. 563:134-145.

*Cité par le Comité d’experts en vigie génomique du SRAS-CoV-2dans: Recommandations pour rehausser la surveillance de la lignée B.1.1.529 (Omicron) du SRAS-CoV-2 au Québec

Cited by Stanford Coronavirus Antiviral & Resistance Database (CoVDB) in Susceptibility of variants

 Prévost J., Richard J., Gasser R., Ding S., Fage C., Anand SP., Adam D., Vergara NG., Tauzin A., Benlarbi M., Gong SY., Goyette G., Privé A., Moreira S., Charest H., Roger M., Mohtes W., Pazgier M., Brochiero E., Boivin G., Abrams CF., Schön A. and Finzi A.  Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2.  Journal of Biological Chemistry. 2021. 297(4):101151*corresponding authors *choix de l’éditeur

 Soto, J. C., Barakat, M., Hutter, J. A., Kiely, M., Moreira, S., Shapiro, B. J., Murall, C. L., Parenteau, N., Désilets, J., & Lessard, R. (2021). Outbreak investigation of SARS-CoV-2 transmission in an emergency childcare centre. Canadian Journal of Public Health. Revue Canadienne de Sante Publique. https://doi.org/10.17269/s41997-021-00544-1

 Mubarak, S., McArthur, A., & Moreira, S. (2021, March 16). SARS-CoV-2 variants of concern remind us that we underestimate biology at our own peril. The Globe And Mail. https://www.theglobeandmail.com/canada/article-sars-cov-2-variants-of-concern-remind-us-that-we-underestimate-biology/

 Carmen Lia Murall*, Eric Fournier*, Jose Hector Galvez, Sarah J. Reiling, Pierre-Olivier Quirion, Anne-Marie Roy, Shu-Huang Chen, Paul Stretenowich, Mathieu Bourgey, Mark Lathrop, Michel Roger, Guillaume Bourque, Jiannis Ragoussis, B. Jesse Shapiro, Sandrine Moreira, on behalf of the CoVSeQ Consortium  Genomic epidemiology of early introductions of SARS-CoV-2 into the Canadian province of Québec, Murall et al, 2020  https://virological.org/t/genomic-epidemiology-of-early-introductions-of-sars-cov-2-into-the-canadian-province-of-quebec/553  [Blog avant publication] *equal contribution

 Tardif J-C, Bouabdallaoui N, L’Allier PL… and Boivin G. Colchicine for Community-Treated Patients with COVID-19: A Randomised, Double-Blinded, Adaptive, Controlled Trial. The Lancet Respiratory Medicine2021; 9:924-932

 Zinszer K, McKinnon B, … Boivin G, De Serres G, Quach C. Seroprevalence of Anti-SARS-CoV-2 Antibodies Among School and Daycare Children and Personnel: Protocol for a Cohort Study in Montreal, Canada. British Medical Journal Open2021; 11:e53245.

 Niesor E, Boivin G, Rheaume E, Shi R, Lavoie V, Goyette N, Picard M-E, Perez A, Lghrissi-Thode F, Tardif J-C. Inhibition of the Main 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. American Chemistry Society Omega2021; 6:16584-16591.

 Dubé M-P, Lemacon A, Barhadi A, …Boivin G, Busseuil D, Tardif J-C. Genetics of Symptom Remission in Outpatients with COVID-19. Scientific Reports2021; 11:10847.

 Piret J, Boivin G. Pandemics Throughout History. Frontiers in Microbiology2021; 11:631736.

 Longtin Y, Charest H, Quach C, Savard P, Baz M, Boivin G, Fafard J, Villeneuve J, Roger M, De Serres G. Infectivity  of Healthcare Workers with SARS-CoV-2 Infection 14 Days After Onset of Symptoms: A Cross-Sectional Study. Infection Control and Hospital Epidemiology2021; 11:1-3.

 Beaudoin-Bussières G., Richard J*., Prévost J., Goyette G. and Finzi A*.  A new flow cytometry assay to measure antibody dependent cell-mediated cytotoxicity against SARS-coV-2 Spike expressing cells.  STAR Protocols. 2021. 2(4):100851. doi: 10.1016/j.xpro.2021.100851. *corresponding authors

 Bégin P#., Callum J#., Jamula E., Cook R., Heddle NM., Tinmouth A., Zeller MP., Beaudoin-Bussières G., Amorim L., Bazin R., Loftsgard KC., Carl R., Chassé M., Cushin MM., Daneman N., Devine DV., Dumaresq J., Fergusson DA., Gabe C., Glesby MJ., Li N., Liu Y., McGeer A., Robitaille N., Sachais BS., Scales DC., Schwartz L., Shehata N., Turgeon AF., Wood H., Zarychanski R., Finzi A. and Arnold DM#. Convescent plasma for hopsitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial.  Nature Medicine. 2021. 27(11):2012-2024 doi: 10.1038/s41591-021-01488-2. #co-corresponding.

 Ullah I*., Prévost J*., Ladinsky M., Stone H., Lu M., Anand SP., Beaudoin-Bussières G., Symmes K., Benlarbi M., Ding S., Gasser R., Fink C., Chen Y., Tauzin A., Goyette G., Bourassa C., Medjahed H., Mack M., Chung K., Wilen CB., Dekaban GA., Dikeakos JD., Bruce EA., Kaufmann DE., Stamatatos L., McGuire AT., Richard J., Pazgier M., Bjorkman PJ., Mothes W., Finzi A#., Kumar P#., Uchil PD#. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy.  Immunity. 2021. 54(9):2143-2158.e15*co-first, #co-corresponding

*Highlighted in Gonzalez and Wang. Illuminating the Fc-dependence of SARS-CoV-2 neutralization. Immunity. 2021. S1074-7613(21)00358-7.

 Murall, C. L., Mostefai, F., Grenier, J.C, Poujol, R., Hussin, J., Moreira, S., Shapiro, J.B., on behalf of the CoVSeQ consortium (2021). Recent evolution and international transmission of SARS-CoV-2 clade 19B (Pango A lineages). Site virological.org. https://virological.org/t/recent-evolution-and-international-transmission-of-sars-cov-2-clade-19b-pango-a-lineages/711 [Blog avant publication]

 Murall, C. L., Fournier, E., Galvez, J. H., N’Guessan, A., Reiling, S. J., Quirion, P.-O., Naderi, S., Roy, A.-M., Chen, S.-H., Stretenowich, P., Bourgey, M., Bujold, D., Gregoire, R., Lepage, P., St-Cyr, J., Willet, P., Dion, R., Charest, H., Lathrop, M., … Moreira, S. (2021). A small number of early introductions seeded widespread transmission of SARS-CoV-2 in Québec, Canada. Genome Medicine, 13(1), 169.

 Tauzin A*., Nayrac M*., Benlarbi M., Gong SY., Gasser R., Beaudoin-Bussières G., Brassard N., Laumaea A., Vézina D., Prévost J., Anand SP., Bourassa C., Gendron-Lepage G., Medjahed H., Goyette G., Niessl J., Tastet O., Gokool L., Morrisseau C., Arlotto P., Stamatatos L., McGuire AT., Larochelle C., Uchil P., Lu M., Mothes W., De Serres G., Moreira S., Roger M., Richard J., Martel-Laferrière V., Duerr R., Tremblay C#., Kaufmann DE#. and Finzi A#.   A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses.  Cell Host and Microbe. 2021. S1931-3128(21)00279-1.

*Highlighted in Damani-Yokota, Yeung and Khanna. Beyond neutralization for BNT162b2 mRNA vaccinaton. Cell Host and Microbe. 2021. 29:1033-1035.

*Cité par le Comité sur l’immunisation du Québec dans: Administration de la 2e dose des vaccins contre la COVID-19 chez les résidents de CHSLD en contexte de début d’une troisième vague pandémique et d’une couverture vaccinale sous-optimale chez les travailleurs de la santé de ces milieux

*Cited by The Office of the Chief Science Advisor of Canada in: Scientific Considerations for Using COVID-19 Vaccination Certificates

 Jennewein MF., MacCamy AJ., Akins NR., Feng J., Homad LJ., Hurlburt NK., Seydoux E., Wan YH., Stuart AB., Edara VV., Floyd K., Vanderheiden A., Mascola JR., Doria-Rose N., Wang L., Yang ES., Chu HY., Torres JL., Ozorowski G., Ward AB., Whaley RE., Cohen KW., Pancera M., McElrath MJ., Englund JA., Finzi A., Suthar MS., McGuire AT., Stamatatos L.   Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.  Cell Reports. 2021. 36(2):109353.

 Bégin P., Callum J., Heddle NM., Cok R., Zeller MP., Tinmouth A., Fergusson DA., Cushing MM., glesby MJ., Chassé M., Devine DV., Robitaiile N., Bazin R., Shehata N., Finzi A., McGeer A., Cales DC., Schwartz L., Turgeon AF., Zarychanski R., Daneman N., Carl R., Amorim L., Gabe C., Ellis M., Sachais BS., Loftsgard KC., Jamula E., Carruthers J., Duncan J., Lucier K., Li N., Liu Y., Armali C., Kron A., Modi D., Auclair MC., Cerro S., Avram M., Arnold DM. Convalest plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international multicentre, randomized, open label trial. Trials. 2021. 22(1):323. doi: 10.1186/s13063-021-05235-3.

 Goupil R*., Mehdi B*., Beaubien-Souligny W., Nadeau-Fredette AC., Chatterjee D., Goyette G., Gunaratnam L., Lamarche C., Tom A., Finzi A#. and Suri R#.   Short-term antibody response after one dose of BNT162b2 vaccine in patients receiving hemodialysis: A report from the Quebec Renal Network COVID-19 study. CMAJ. 2021. 193(22):E793-E800. *co-first #co-corresponding.

*Cité par le Comité sur l’immunisation du Québec dans: Intervalle entre les deux doses des vaccins à ARN messager contre la COVID-19 chez les personnes immunosupprimées

*Cited by Government of Ontario. Ministry of Health in: Vaccine Clinical Advisory Group (VCAG) Recommendations on Exceptions to Extended Dose Intervals for COVID-19 vaccines

 Papenburg J., Cheng MP., Corsini R., Caya C., Mendoza E., Manguiat K., Lindsay RL., Wood H., Drebot M., Dibernardo A., Zaharatos G., Bazin R., Gasser R., Benlarbi M., Gendron-Lepage G., Beaudoin-Bussières G., Prévost J., Finzi A., Ndao M., Yansouni CP.   Evaluation of a commercial culture-free neutralization antibody detection kit for sever acute respiratory syndrome-related coronavirus-2 and comparison with an anti-RBD ELISA assay. Open Forum Infectious Diseases. 2021. 8(6):ofab220.

 Anand SP*., Prévost J*., Nayrac M*., Beaudoin-Bussières G*., Benlarbi M., Gasser R., Brassard N., Laumaea A., Gong SY., Bourassa C., Brunet-Ratnasingham E., Medjahed H., Gendron-Lepage G., Goyette G., Gokool L., Morrisseau C., Bégin P., Martel-Laferrière V., Termblay C., Richard J., Bazin R., Duerr R#., Kaufmann DE# and Finzi A#.   Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.  Cell Reports Medicine. 2021. 2(6):100290.  *Co-first; #co-corresponding

 Lewin A., Therrien R., De Serres G., Grégoire Y., Perreault J., Drouin M., Fournier MJ., Tremblay T., Beaudoin J., Beaudoin-Bussières G., Prévost J., Gendron-Lepage G., Finzi A., Bernier F., Bazin R., Germain M., Delage G. SARS-CoV-2 seroprevalence among blood donors in Québec, with symptoms associated with seropositivity : a nested case-control study. Canadian Journal of Public Health.  2021.  112(4):576-586.

 Stamatatos L., Czartoski J., Wan YH., Homad LJ., Rubin V., Glantz H., Neradilek M., Seydoux E., Jennewein MF., MacCamy AJ., Feng J., Mize G., De Rosa SC., Finzi A., Lemos MP., Cohen KW., Moodie Z., McElrath J., McGuire AT. A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science.  2021.  .  372 : 1413–1418.

*Cited by Alberta Health Services, COVID-19 Scientific Advisory Group in: COVID-19 Scientific Advisory Group Evidence Summary and Recommendations

 Prévost J. and Finzi A. The Great Escape? SARS-CoV-2 Variants Evading Neutralizing Responses. Cell Host and Microbe.  2021.  29(3):322-324.

 Rébillard RM., Charabati M., Grasmuck C., Filali-Mouhim A., Tastet O., Brassard N., Daigneault A., Bourbonnière L., Anand SP., Balthazard R., Beaudoin-Bussières G., Gasser R., Benlarbi M., Moratalla AC., Solorio YC., Boutin M., Farzam-kia N., Descôteaux-Dinelle J., Fournier AP., Gowing E., Laumaea A., Jamann H., Lahav B., Goyette G., Lemaître F., Mamane VH., Prévost J., Richard J., Thai K., Cailhier JF., Chomont N., Finzi A., Chassé M., Durand M., Arbour N., Kaufmann DE., Prat A., Larochelle C. Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. Journal of Clinical Investigation. 2021. 145853. doi: 10.1172/JCI145853.

 Gasser R*., Cloutier M*., Prévost J., Fink C., Ducas E., Ding S., Dussault N., Landry P., Tremblay T., Laforce-Lavoie A., Lewin A., Beaudoin-Bussières G., Laumaea A., Medjahed H., Larochelle C., Richard J., Dekaban GA., Dikeakos JD., Bazin R#. and Finzi A#. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Reports. 2021. 34:108790 https://doi.org/10.1016/j.celrep.2021.108790. *equal contribution #co-corresponding

 Anand SP., Prévost J., Richard J., Perreault J., Tremblay T., Drouin M., Fournier MJ., Lewin A., Bazin R., and Finzi A. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. Transfusion. 2021. doi: 10.1111/trf.16318.

 Longtin Y, Charest H, Quach C, Savard P, Baz M, Boivin G, Farfard J (SIC), Villeneuve J, Roger M, De Serres G. Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infect Control Hosp Epidemiol. 2021 Jan 11:1-3. doi: 10.1017/ice.2020.1420. Epub ahead of print.

2020

 Therrien C., Serhir B., Bélanger-Collard M., Skrzypczak J., Shank DK., Renaud C., Girouard J., Loungnarath V., Carrier M., Brochu G., Tourangeau F., Gilfix B., Piché A., Bazin R., Lavoie M., Martel-Laferrière V., Fortin C., Benoit A., Marcoux D., Gauthier N., Laumaea AM., Gasser R., Finzi A, Roger M. Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of ten high throughput serological assays used in clinical laboratories. Journal of Clinical Microbiology. JCM.02511-20. doi: 10.1128/JCM.02511-20.

 Lu M., Uchil PD., Li W., Zheng D., Terry DS., Gorman J., Shi W., Zhang B., Zhou T., Ding S., Gasser R., Prévost J., Beaudoin-Bussières G., Anand SP., Laumaea A., Grover JR., Liu L., Ho DD., Mascola JR., Finzi A., Kwong PD., Blanchard SC., Mothes W. Real-time conformational dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host and Microbe.  2020. 28(6):880-891.e8.

*Highlighted in Serrao and Lee. “FRETing over SARS-CoV-2: Conformational dynamics of the Spike Glycoprotein. Cell Host and Microbe. 2020. 28:778-779

 Ding S., Laumaea A., Benlarbi M., Beaudoin-Bussières G., Gasser R., Medjahed H., Pancera M., Stamatatos L., McGuire A., Bazin R. and Finzi A. Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization. Viruses. 2020. 12(11):E1214.

 Beaudoin-Bussières G., Laumaea A., Anand SP., Prévost J., Gasser R., Goyette G., Medjahed H., Perreault J., Tremblay T., Lewin A., Gokool L., Morrisseau C., Bégin P., Tremblay C., Martel-Laferrière V., Kaufmann DE., Richard J., Bazin R. and Finzi A. Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. mBio. 2020. 11(5):e02590-20. *choix de l’éditeur

 Anand SP., Chen Y., Prévost J., Gasser R., Beaudoin-Bussières G., Abrams C., Pazgier M and Finzi A. Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARSCov-2 S glycoproteins. Viruses. 2020. 12(10):E1104.

 Prévost J*., Gasser R*., Beaudoin-Bussières G*., Richard J*., Duerr R*., Laumaea A*., Anand SP., Goyette G., Benlarbi M., Ding S., Medjahed H., Lewin A., Perreault J., Tremblay T., Gendron-Lepage G., Gauthier N., Carrier M., Marcoux D., Piché A., Lavoie M., Benoit A., Loungnarath V., Brochu G., Haddad E., Stacey HD., Miller MS., Desforges M., Talbot PJ., Gould Maule GT., Côté M., Therrien C., Serhir B., Bazin R., Roger M. and Finzi A.   Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike.  Cell Reports Medicine. 2020. 1(7):100126.

 Perreault J., Tremblay T., Fournier MJ., Drouin M., Beaudoin-Bussières G., Prévost J., Lewin A., Bégin P., Finzi A., and Bazin R. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples withing four months after symptom onset. Blood. 2020. 136(22):2588-2591.

Other Public health recommendations from members of our group

État de situation sur le variant B.1.617 du SRAS-CoV-2 (émergent d’Inde) et recommandations pour en rehausser la surveillance au Québec

Définitions provisoires des cas de réinfection par le SRAS-CoV-2 à des fins de vigie

État de situation sur le variant B.1.617 du SRAS-CoV-2 (émergent d’Inde) et recommandations pour en rehausser la surveillance au Québec

Preprint manuscripts

Alexandra TauzinShang Yu GongMark M. PainterRishi R. GoelDebashree ChatterjeeGuillaume Beaudoin BussièresLorie MarchittoMarianne BoutinAnnemarie LaumaeaJames OkenyGabrielle Gendron-LepageCatherine BourassaHalima MedjahedGuillaume GoyetteJustine C. WilliamsYuxia BoLaurie GokoolChantal MorrisseauPascale ArlottoRenée BazinJudith FafardCécile TremblayDaniel E. KaufmannGaston De SerresMarceline CôtéRalf DuerrValérie Martel-LaferrièreAllison R. GreenplateE. John WherryAndrés Finzi. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.

Brad Pickering, Oliver Lung, Finlay Maguire, Peter Kruczkiewicz, Jonathon D Kotwa, Tore Buchanan, Marianne Gagnier, Jennifer Guthrie, Claire Jardine, Alex Marchand-Austin, Ariane Masse, Heather McClinchey, Kuganya Nirmalarajah, Patryk Aftanas, Juliette Blais-Savoie, Hsien-Yao Chee, Emily Chien, Winfield Yim, Melissa Goolia, Matthew Suderman, Mathieu Pinette, Greg Smith, Daniel Sullivan, Jossip Rudar, Elizabeth Adey, Michelle Nebroski, Marceline Cote, Genevieve Laroche, Allison McGeer, Larissa Nituch, Samira Mubareka, Jeff Bowman. Highly divergent white-tailed deer SARS-CoV-2 with potential deer-to-human transmission bioRxiv 2022.02.22.481551; doi: https://doi.org/10.1101/2022.02.22.481551

Mehdi Benlarbi, Geneviève Laroche, Corby Fink, Kathy Fu, Rory P. Mulloy, Alexandra Phan, Ardeshir Ariana, Corina M. Stewart, Jérémie Prévost, Guillaume Beaudoin-Bussières, Redaet Daniel, Yuxia Bo, Julien Yockell-Lelièvre, William L. Stanford, Patrick M. Giguère, Samira Mubareka, Andrés Finzi, Gregory A. Dekaban, Jimmy D. Dikeakos, Marceline Côté. Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron bioRxiv 2022.02.19.481107; doi: https://doi.org/10.1101/2022.02.19.481107

Parker E, Anderson C, Zeller M, Tibi A, Havens JL, Laroche G, Benlarbi M, Ariana A, Robles-Sikisaka R, Latif A, Watts A, Awidi A, Jaradat SA, Gangavarapu K, Kurzban E, Matteson NL, Han AX, Hughes LD, McGraw M, Spencer E, Nicholson L, Khan K, Suchard MA, Wertheim JO, Wohl S, Côté M, Abdelnour A, Andersen KG, Abu-Dayyeh I. Regional connectivity drove bidirectional transmission of SARS-CoV-2 in the Middle East during travel restrictions. bioRxiv. 2022. doi: https://doi.org/10.1101/2022.01.27.22269922

 Chen Y, Sun L, Ullah I, Beaudoin-Bussières G, Anand SP, Hederman AP, Tolbert WD, Sherburn R, Nguyen DN, Marchitto L, Ding S, Wu D, Luo Y, Gottumukkala S, Moran S, Kumar P, Piszczek G, Mothes W, Ackerman ME, Finzi A, Uchil PD, Gonzalez FJ, Pazgier M. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. bioRxiv [Preprint]. 2021 Nov 24:2021.11.24.469776. doi: 10.1101/2021.11.24.469776. PMID: 34845451; PMCID: PMC8629194.